No open-market selling at TScan Therapeutics, Inc. in the past year, which is unusual. Instead one the people running the company added about $146,000 worth of TCRX.
Lynx1 Capital Management LP (10% Owner) made the biggest buy, worth around $72,000.
No open-market insider buying or selling in the last full quarter. Insiders bought in 2 of the last 7 full quarters. 59 investment managers listed TCRX in their latest 13F filings (Q2 2026); more funds bought than sold.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Dec 23, 2025 | Lynx1 Capital Management LP | 10% Owner | Buy | 80,069 | $0.90 | $72K | SEC |
| Dec 23, 2025 | Lynx1 Capital Management LP | 10% Owner | Buy | 6,232 | $0.90 | $6K | SEC |
| Dec 23, 2025 | Lynx1 Capital Management LP | 10% Owner | Buy | 75,500 | $0.90 | $68K | SEC |
| May 21, 2025 | Lynx1 Capital Management LP | 10% Owner | Buy | 1,200,000 | $1.20 | $1.4M | SEC |
| May 21, 2025 | Lynx1 Capital Management LP | 10% Owner | Buy | 1,388,794 | $1.20 | $1.7M | SEC |
| Dec 16, 2024 | Nichols Weston | 10% Owner | Buy | 100,000 | $2.90 | $290K | SEC |
| Dec 16, 2024 | Nichols Weston | 10% Owner | Buy | 31,800 | $3.01 | $96K | SEC |
| Nov 19, 2024 | Nichols Weston | 10% Owner | Buy | 947 | $4.34 | $4K | SEC |
| Sep 24, 2024 | Klencke Barbara | Director | Buy | 5,000 | $5.29 | $26K | SEC |
| Aug 27, 2024 | Klencke Barbara | Director | Buy | 5,000 | $5.53 | $28K | SEC |
| Aug 27, 2024 | Klencke Barbara | Director | Buy | 5,000 | $5.69 | $28K | SEC |
| Aug 27, 2024 | ZDRAVESKI ZORAN | Officer | Sell | 164,686 | $5.78 | $952K | SEC |
| Dec 21, 2023 | BARBERICH TIMOTHY J | Director | Buy | 28,830 | $4.89 | $141K | SEC |
| Dec 21, 2023 | BARBERICH TIMOTHY J | Director | Buy | 317 | $4.97 | $2K | SEC |
| Dec 18, 2023 | Klencke Barbara | Director | Buy | 5,000 | $5.08 | $25K | SEC |
In the last 12 months TScan Therapeutics, Inc. insiders made open-market purchases worth about $146,000 and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in TCRX was filed on 2025-12-23.
59 investment managers reported holding TCRX in SEC Form 13F filings for Q2 2026.
No congressional trades in TCRX were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).